Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan.
Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Stem Cells. 2018 Mar;36(3):434-445. doi: 10.1002/stem.2759. Epub 2017 Dec 27.
A substantial proportion of patients with acute graft-versus-host disease (aGVHD) respond to cell therapy with culture-expanded human bone marrow mesenchymal stromal/stem cells (BM-MSCs). However, the mechanisms by which these cells can ameliorate aGVHD-associated complications remain to be clarified. We show here that BM-MSC-derived extracellular vesicles (EVs) recapitulated the therapeutic effects of BM-MSCs against aGVHD. Systemic infusion of human BM-MSC-derived EVs prolonged the survival of mice with aGVHD and reduced the pathologic damage in multiple GVHD-targeted organs. In EV-treated GVHD mice, CD4+ and CD8+ T cells were suppressed. Importantly, the ratio of CD62L-CD44+ to CD62L + CD44- T cells was decreased, suggesting that BM-MSC-derived EVs suppressed the functional differentiation of T cells from a naive to an effector phenotype. BM-MSC-derived EVs also preserved CD4 + CD25 + Foxp3+ regulatory T cell populations. In a culture of CD3/CD28-stimulated human peripheral blood mononuclear cells with BM-MSC-derived EVs, CD3+ T cell activation was suppressed. However, these cells were not suppressed in cultures with EVs derived from normal human dermal fibroblasts (NHDFs). NHDF-derived EVs did not ameliorate the clinical or pathological characteristics of aGVHD in mice, suggesting an immunoregulatory function unique to BM-MSC-derived EVs. Microarray analysis of microRNAs in BM-MSC-derived EVs versus NHDF-derived EVs showed upregulation of miR-125a-3p and downregulation of cell proliferative processes, as identified by Gene Ontology enrichment analysis. Collectively, our findings provide the first evidence that amelioration of aGVHD by therapeutic infusion of BM-MSC-derived EVs is associated with the preservation of circulating naive T cells, possibly due to the unique microRNA profiles of BM-MSC-derived EVs. Stem Cells 2018;36:434-445.
相当一部分急性移植物抗宿主病(aGVHD)患者对经培养扩增的人骨髓间充质基质/干细胞(BM-MSCs)的细胞治疗有反应。然而,这些细胞减轻与 aGVHD 相关并发症的机制仍有待阐明。我们在此表明,BM-MSC 衍生的细胞外囊泡(EVs)再现了 BM-MSCs 对抗 aGVHD 的治疗作用。全身输注人 BM-MSC 衍生的 EV 可延长 aGVHD 小鼠的存活时间,并减轻多个 GVHD 靶向器官的病理损伤。在 EV 治疗的 GVHD 小鼠中,CD4+和 CD8+T 细胞受到抑制。重要的是,CD62L-CD44+与 CD62L+CD44- T 细胞的比值降低,表明 BM-MSC 衍生的 EV 抑制了 T 细胞从幼稚向效应表型的功能分化。BM-MSC 衍生的 EV 还保留了 CD4+CD25+Foxp3+调节性 T 细胞群体。在含有 BM-MSC 衍生 EV 的 CD3/CD28 刺激的人外周血单核细胞培养物中,CD3+T 细胞激活受到抑制。然而,在含有正常人类真皮成纤维细胞(NHDF)衍生 EV 的培养物中,这些细胞没有受到抑制。NHDF 衍生的 EV 不能改善小鼠的 aGVHD 的临床或病理特征,这表明 BM-MSC 衍生的 EV 具有独特的免疫调节功能。BM-MSC 衍生 EV 与 NHDF 衍生 EV 之间 microRNA 的微阵列分析显示,miR-125a-3p 的上调和细胞增殖过程的下调,通过基因本体富集分析鉴定。总之,我们的研究结果首次提供了证据,证明通过治疗性输注 BM-MSC 衍生的 EV 改善 aGVHD 与循环幼稚 T 细胞的保存有关,这可能归因于 BM-MSC 衍生的 EV 的独特 microRNA 谱。干细胞 2018;36:434-445.